Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Ranolazine improves glycaemic control when added to metformin in T2DM patients
Last updated July 18, 2026
Key finding
Combination group achieved a significantly greater HbA1c reduction (mean difference 0.25%, p=0.022).
This study evaluated the efficacy of ranolazine as an add-on therapy to metformin in patients with type 2 diabetes, finding significant improvements in glycemic control.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of ranolazine as an add-on therapy to metformin in patients with type 2 diabetes, finding significant improvements in glycemic control.
Clinical relevance
Improving glycemic control is crucial for managing type 2 diabetes and reducing the risk of complications. The findings suggest that adding ranolazine to standard metformin therapy may enhance treatment outcomes for patients who struggle to achieve adequate blood sugar levels.
Keep in mind
Study design was non-randomized, which may introduce bias. Sample size and demographic details were not specified. Results may not be generalizable to all populations with type 2 diabetes.
Published in
Journal Reference
Publication details and source links for this paper.
Alexander M, John RA, Nidhi K, et al. Efficacy of Ranolazine as an Add-On Therapy to Metformin in Patients with Type 2 Diabetes Mellitus. Cureus. 2026;18(1):e101227. doi:10.7759/cureus.101227
Main Effects
Combination therapy led to a mean HbA1c reduction of 0.25% at three months (p=0.022).
Fasting blood glucose levels were significantly lower in the combination group at three months (p=0.005).
Post-prandial blood glucose levels were significantly lower in the combination group at six months (p=0.027).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin and Fasting Plasma Glucose (FPG), Fasting blood sugar (FBS), Glucose iAUC (OGTT), and 1 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- Fasting Plasma Glucose (FPG)
- Fasting blood sugar (FBS)
- Glucose iAUC (OGTT)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
4
Evidence pairs
579
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Metformin Therapies and Fasting Glucose
Related evidence
Evidence relationship
Metformin Therapies and HbA1c
Save evidence
Evidence relationship
Metformin Therapies and Postprandial and OGTT Glucose
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 78
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Combination therapy showed a significant HbA1c reduction of 0.25% at three months.
- Fasting blood glucose was significantly lower in the combination group (p=0.005).
- Post-prandial blood glucose levels improved significantly at six months (p=0.027).
Who this applies to
- Adults diagnosed with type 2 diabetes mellitus.
- Patients currently on metformin therapy.
Keep in Mind
- The study's non-randomized design may affect the reliability of the findings.
- Further research is needed to confirm these results in larger, diverse populations.
- The long-term effects of adding ranolazine to metformin require additional investigation.
Between the Lines
- Study design was non-randomized, which may introduce bias.
- Sample size and demographic details were not specified.
- Results may not be generalizable to all populations with type 2 diabetes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, Metformin Therapies and Fasting Glucose.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 11 studies
View evidenceMedications
Metformin Therapies → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Supporting studies: Based on 5 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
11 studies
intervention_hubContributes to Metformin Therapies evidence base.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
5 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
11 results
All studies on Metformin and Fasting Plasma Glucose (FPG)
Intervention: MetforminOutcome: Fasting Plasma Glucose (FPG)
5 results
All studies on Metformin
Intervention: Metformin
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
5 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve fasting glucose?
Strong Evidence
Metformin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Consistent | 1 study
- 2
Fasting blood sugar (FBS)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve HbA1c?
Strong Evidence
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.2 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve postprandial and ogtt glucose?
Strong Evidence
Metformin Therapies may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 78.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesEarly use of effective therapies may improve diabetes outcomesPremeal metformin improves postmeal glucose control in diabetes.Sitagliptin with Metformin Improves Metabolic Health
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.